Catalyst calendar
The repricing schedule is mostly public if you actually look at it.
AllI · Sterile fill-finish capacityII · Stoppers, syringes & drug-contact componentsIII · Pharmaceutical glass & vialsIV · Bioprocessing consumables & resinsV · API & small-molecule reshoringVI · CDMO capacity & the China exodusVII · Peptide & oligonucleotide manufacturingVIII · Sterile injectables & shortage economicsIX · Analytical instruments & QC releaseX · Private giants & exposure vehicles
October 2026
- 22mediumEarningsWSTWest Pharmaceutical Q3 2026 resultsReads through to component (stopper/Crystal Zenith) demand and the 49%-owned Daikyo Seiko affiliate — the most central US-listed proxy for the injectable drug-delivery component chokepoint.
- 06lowConferenceCPhI Worldwide 2026, Fiera Milano (Oct 6-8)The largest global API/CDMO sourcing event where reshoring capacity announcements and qualified-supplier deals for non-Chinese API surface and reprice the bench.
- 06lowConferenceCPHI Worldwide 2026, Fiera Milano (Oct 6-8)The premier global CDMO/contract-manufacturing gathering where fill-finish capacity expansions, line awards and qualified-supplier deals are typically announced.
- 06lowConferenceCPHI Worldwide 2026 (Oct 6-8)The global pharma-manufacturing supply-chain meeting where CDMO capacity signals (biologics drug substance, aseptic fill-finish) and BIOSECURE re-shoring intent are set — directly drives the supplier-qualification choke this vertical tracks.
November 2026
- 05mediumEarningsCRLCharles River Q3 2026 earnings (estimated)Preclinical booking trends and any strategic-review outcome test whether Western biotechs are de-risking away from China-based research partners as the thesis assumes.
December 2026
- 18highPolicyBIOSECURE Act: OMB list of biotechnology companies of concern due (statutory deadline)Designating which Chinese biomanufacturing/CDMO entities are restricted sets the China-de-risking tailwind for Western consumable and resin suppliers, replacing the now-settled question of passage.
- 18highPolicyOMB deadline to publish initial BIOSECURE 'biotechnology companies of concern' listStatutory one-year deadline that converts the WuXi 1260H designation into a formal BCOC pathway and is the next hard regulatory reprice for the entire CDMO bench.
- 18highPolicyBIOSECURE Act — OMB initial 'companies of concern' designation list due (within 12 months of Dec 18, 2025 enactment)Naming Chinese biotech entities (e.g. WuXi) under the now-enacted BIOSECURE Act sharpens the reshoring tailwind for US/EU drug manufacturing and the qualified-component suppliers feeding it.
- 18highPolicyBIOSECURE Act OMB 'companies of concern' initial list deadline (one year from enactment)Frames the US-onshoring tailwind backing BARDA-funded domestic vial capacity, even though the Act targets Chinese biotech CDMO services rather than glass packaging directly.
- 31highPolicyOMB statutory deadline to publish BIOSECURE list of biotechnology companies of concernNaming the companies of concern is the moment the BIOSECURE Act becomes operationally binding, repricing both Chinese CDMOs and their non-Chinese substitutes for US-API work.
- 31highPolicyOMB BIOSECURE 'biotechnology company of concern' list dueOMB's formal list operationalizes BIOSECURE and signals how fast federal demand will steer peptide/oligo API orders away from Chinese CDMOs toward Western capacity.
January 2027
- 15highPolicyGDUFA IV negotiated agreement statutory submission deadline to CongressGDUFA IV (FY2028-2032) explicitly weighs onshoring and domestic-production incentives that shape whether US sterile-injectable capacity gets built; the agreement must reach Congress by this date.
- 01mediumProgramSTVNStevanato Fishers (Indiana) and Latina (Italy) RTU cartridge lines targeted commercial late 2026/early 2027The transition of these announced lines from construction to qualified output is the milestone that either relieves or extends the GLP-1 cartridge bottleneck at the heart of the choke.
Past
- 2026-08-26Agilent Q3 FY2026 earnings
- 2026-08-26Agilent fiscal Q3 2026 earnings
- 2026-08-13Hikma Pharmaceuticals H1 2026 interim results (estimated, mirrors early-August 2025 timing)
- 2026-08-12SCHOTT Pharma Q3 FY2026 quarterly statement
- 2026-08-06Amphastar Pharmaceuticals Q2 2026 earnings
- 2026-08-06Charles River Q2 2026 earnings
- 2026-08-06Stevanato Group Q2/H1 2026 results
- 2026-08-06Hikma Pharmaceuticals H1 2026 interim results
- 2026-08-05Novo Nordisk H1 2026 financial results
- 2026-08-05Novo Nordisk H1 2026 financial report
- 2026-08-04Stevanato Group Q2 2026 results
- 2026-08-04Stevanato Group Q2 2026 earnings
- 2026-08-04Waters Q2 2026 earnings — first full quarter as combined Waters/BD entity
- 2026-08-04Repligen Q2 2026 results
- 2026-07-31Section 232 pharmaceutical tariffs take effect (100% on patented pharma & APIs)
- 2026-07-30Baxter International Q2 2026 earnings (estimated late July/early August)
- 2026-07-30Mettler-Toledo Q2 2026 earnings
- 2026-07-29Samsung Biologics Q2 2026 financial results
- 2026-07-28Corning Q2 2026 earnings
- 2026-07-28Danaher Q2 2026 results
- 2026-07-24Bachem H1 2026 half-year results
- 2026-07-23FDA classification decision on Novo Nordisk's Bloomington, IN fill-finish site
- 2026-07-23West Pharmaceutical Q2 2026 results
- 2026-07-23Sartorius AG H1 2026 results
- 2026-07-22Thermo Fisher Scientific Q2 2026 earnings
- 2026-07-22Lonza Half-Year 2026 results